Matsukiyococokara & Co. · TSE:3088
Matsukiyococokara & — FY2023 Earnings Presentation
16 slides from Matsukiyococokara &'s earnings presentation, May 10, 2024
Slide 1: Supplementary Presentation Financial Results for the Fiscal Year Ended March 31, 2024
Supplementary Presentation Financial Results for the Fiscal Year Ended March 31, 2024 Copyright 2024 May 10, 2024 MatsukiyoCocokara & Co. All rights Reserved. MatsukiyoCocokara & Co.
Slide 2: Table of Contents
Table of Contents Financial Summary (Full Year) ・・・・・・ 3 Segment Results (Full Year) ・・・・・・ 4 Segment Results (Full Year) ) (Reference) ・・・・・・ 5 Excluding amortization of goodwill and trademark rights associated with the management integration with cocokarafine Inc. Net Sales by Product ・・・・・・ 6 Bal
Slide 3: Financial Summary (Full Year)
Financial Results for FY2023 Financial Summary (Full Year) Steady implementation of key strategies and realization of management integration synergies led to increases in both sales and profit Operating profit margin improved 0.9pt to 7.4% from 6.5% in YoY due to appropriate cost control (Millio
Slide 4: Segment Results (Full Year)
Financial Results for FY2023 Segment Results (Full Year) Matsumotokiyoshi Group business achieved a significant increase in sales and double-digit profit growth; Cocokarafine Group business achieved an increase in sales and double-digit profit growth Cocokarafine Group business continues to impr
Slide 5: Segment Results (Full Year) (Reference)
Financial Results for FY2023 Segment Results (Full Year) Excluding amortization of goodwill and trademark rights totaling 7,237 million yen Reference associated with the management integration with cocokarafine Inc. (Millions of yen) FY2022 FY2023 Change Change Profitable Profitable (amount) (%) (%)
Slide 6: Net Sales by Product
Financial Results for FY2023 Net Sales by Product Significant increase in our focused health and beauty category Minimize the reactionary decline in COVID-19 related products with high gross profit margins by steadily implementing key strategies (Millions of yen) Net sales Gross profit margin(％)
Slide 7: Balance Sheet
Financial Results for FY2023 Balance Sheet Equity ratio increased slightly from the end of the previous fiscal year (70.1% ⇒ 71.0%) Liabilities for retirement benefit decreased due to revision of retirement benefit plan at some group companies (Millions of yen) End of March, 2023 End of March, 2
Slide 8: Statement of Cash Flows
Financial Results for FY2023 Statement of Cash Flows Approximately 41 billion yen of free cash flow was generated (Millions of yen) End of March, 2023 End of March, 2024 Change Cash flows from operating activities 64,061 63,506 (554) Cash flows from investing activities (19,669) (22,760) (3,090) C
Slide 9: Store Openings, Closings, and Renovations in Japan
Financial Results for FY2023 Store Openings, Closings, and Renovations in Japan Focus on careful store openings in light of rising rents, construction costs, and supplies costs Promoted scrap-and-build to respond to changes in store history, sales floor space, and market area (Unit: No. of store
Slide 10: FY2024 Financial Forecasts
Financial Forecasts for FY2024 FY2024 Financial Forecasts (Millions of yen) First Half 1H FY2023 1H FY2024 Change Change % to net sales % to net sales (amount) (%) Net sales 507,766 515,000 7,233 1.4 Gross profit 173,826 34.2 178,000 34.6 4,173 2.4 SG & A 136,272 26.8 140,000 27.2 3,727 2.7 Operatin
Slide 11: Store openings, closings, and renovations plan in Japan
Financial Forecasts for FY2024 Store openings, closings, and renovations plan in Japan Focus on careful store openings in light of rising rents, construction costs, and supplies costs Promoted scrap-and-build to respond to changes in store history, sales floor space, and market area (Unit: No. o
Slide 12: Shareholder Return Policy
Financial Forecasts for FY2024 Shareholder Return Targets set for DOE (dividend on equity) of at least 3% and dividend payout ratio of at least 30%. We have introduced a progressive dividend policy, whereby dividends are maintained or increased. We will flexibly implement share buyback, 円 35 t
Slide 13: Appendix: Quarterly Consolidated Financial Results
【Appendix】 Financial Results for FY2023 Quarterly Consolidated Financial Results FY2022 FY2023 （Millions of yen/%） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Net sales 227,209 237,865 249,201 236,971 951,247 248,222 259,544 262,566 252,197 1,022,531 Gross profit 76,674 82,959 86,550 83,136 329,320
Slide 14: Appendix: Quarterly Segment Results
【Appendix】 Financial Results for FY2023 Quarterly Segment Results FY2022 FY2023 （Millions of yen/％） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 134,802 141,473 151,124 145,134 572,535 152,810 159,867 162,999 157,439 633,117 Matsumoto- kiyoshi Segment profit 8,909 9,891 12,940 10,055 41,797 11,
Slide 15: Appendix: Quarterly Net Sales and Gross Profit by Product
【Appendix】 Financial Results for FY2023 Quarterly Net Sales and Gross Profit by Product FY2022 FY2023 (Millions of yen/％) 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 76,177 83,068 87,365 87,736 334,348 85,192 91,340 93,264 92,095 361,892 Medical and pharmaceuti Segment profit 30,988 36,963 37,
Slide 16: Cautionary Statement
Cautionary Statement This document contains future outlooks such as plans, forecasts, strategies, and others which are not historical fact and these are made by the management’s judgement based on the obtainable information at the time of the disclosure. Actual results may significantly differ from